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Obesity is amajor health burdenwith an increased risk of cardiovascularmorbidity andmortality. Endothelial dysfunction is pivotal
to the development of cardiovascular disease (CVD). In relation to this, adipose tissue secreted factors termed “adipokines” have
been reported to modulate endothelial dysfunction. In this review, we focus on two of the most abundant circulating adipokines,
that is, leptin and adiponectin, in the development of endothelial dysfunction. Leptin has been documented to influence amultitude
of organ systems, that is, central nervous system (appetite regulation, satiety factor) and cardiovascular system (endothelial
dysfunction leading to atherosclerosis). Adiponectin, circulating at a much higher concentration, exists in different molecular
weight forms, essentially made up of the collagenous fraction and a globular domain, the latter being investigated minimally for
its involvement in proinflammatory processes including activation of NF-𝜅𝛽 and endothelial adhesion molecules. The opposing
actions of the two forms of adiponectin in endothelial cells have been recently demonstrated. Additionally, a local and systemic
change to multimeric forms of adiponectin has gained importance. Thus detailed investigations on the potential interplay between
these adipokines would likely result in better understanding of the missing links connecting CVD, adipokines, and obesity.
1. Introduction
Obesity is a global epidemic with serious health complica-
tions. In particular, obesity is associatedwith elevated free fat-
ty acid levels, leading to the development of insulin resis-
tance, diabetes, and cardiovascular disease (CVD) [1–3]. The
development of CVD is characterised by impaired nitric
oxide (NO) release from vascular endothelium and decreased
blood flow to insulin target tissues resulting in insulin resis-
tance, termed as endothelial dysfunction [4]. However, the
mechanisms by which obesity causes both insulin resistance
and vascular dysfunction are not fully understood. In this
respect, increasing attention has been paid to the direct
vascular effects of adipose tissue (AT) derived factors termed
“adipokines” or “adipocytokines” which have been docume-
nted to affect endothelial function [5]. A few of these adipok-
ines are characterised by their favourable effects to main-
tain the body’s energy and vascular homeostasis; however,
adipokines have also been implicated in the pathogenesis of
obesity-related disorders, such as atherosclerosis, specifically,
by increasing the expression of proangiogenic/proatheroge-
nic factors like endothelial gelatinases (matrix metallopro-
teinases 2 and 9) and vascular endothelial growth factor
(VEGF) [6]. Leptin, adiponectin, monocyte chemoattractant
protein- (MCP-) 1, plasminogen activator inhibitor- (PAI-)
1, tumour necrosis factor (TNF) 𝛼, interleukin- (IL-) 6, and
resistin are a fewof these adipokines implicated in endothelial
dysfunction [5].
2. Obesity and Molecular Aspects of
Endothelial Dysfunction
Endothelial dysfunction in obesity is characterised by increa-
sed generation of oxygen-derived free radicals (ROS) [7].This
is contributed by vascular cells and inflamed hypertrophied
adipocytes as a result of endoplasmic reticulum (ER) stress
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and mitochondrial dysfunction [8]. Enzymes of mitochon-
drial electron transport chain, xanthine oxidase, cyclooxy-
genases, lipoxygenases, myeloperoxidases, cytochrome P450
monooxygenase, heme oxygenases, peroxidases, and NAD-
(P)Hoxidases contribute to endothelial dysfunction [7]. Unc-
oupling of endothelial nitric oxide synthase (eNOS) is amajor
contributor to ROS production [9]. This results in decreased
NO (nitric oxide) bioavailability, increased O
2
− production,
and formation of peroxynitrite (ONOO−), a key mediator of
lipid peroxidation and foam cell formation in atherosclerotic
lesions [10]. Additionally, ROS accumulation results in acti-
vation of signalling cascades that regulate transcription fac-
tors, including NF-𝜅𝛽 (nuclear factor kappa beta) adhesion
molecules, chemotactic factors, antioxidant enzymes, and
vasoactive substances promoting adhesion and migration of
circulating monocytes initiating atherosclerotic lesions [11].
Dysregulated adipokine production leading to increasedROS
generation forms a major feedback loop in initiation, main-
tenance, and progression of endothelial dysfunction [12].
Adiponectin and leptin are the two widely studied most-
abundant, circulating adipokines. In this review, we discuss
the diverse roles of leptin and adiponectin in endothelial dys-
function with emphasis on proangiogenic/proatherogenic
factors in the endothelial cells.
3. Adiponectin
Adiponectin, the most abundantly secreted adipokine (2–
20𝜇g/mL in circulating plasma), was first identified as
Acrp30—adipose complement-related protein of 30 kDa
[13]—because of its high similarity to complement protein.
Adiponectin exerts its insulin-sensitizing effects by increas-
ing 𝛽-oxidation of fatty acids, in the process reducing serum
triglyceride and levels of free-fatty acids, and thus indirectly
improving insulin sensitivity of the liver [14]. In addition to
its metabolic actions, adiponectin is also reported to pos-
sess antiatherogenic and anti-inflammatory properties [15].
Circulating low adiponectin levels (hypoadiponectinemia) is
considered an independent risk factor for endothelial dysfun-
ction and modulating vessel wall health [16].
Adiponectin is a 247-amino acid protein with four doma-
ins, an amino-terminal signal sequence, a variable region, a
collagenous domain, and a carboxy-terminal globular dom-
ain [13, 17–19], and undergoes posttranslational modifica-
tions within the adipocytes into multimeric forms including
trimers, hexamers, and high-molecular-weight (HMW) olig-
omers [20]. More importantly, cleavage of globular domain
of full-length adiponectin (fAD) by activated monocytes has
been reported to conversely affect the protective role of fAD
[21].
Both globular adiponectin (gAD) and fAD exert their
effects via transmembrane G-protein coupled receptors, adi-
ponectin receptor 1 (AdipoR1), and adiponectin receptor
2 (AdipoR2) [22]. These receptors have been described as
structurally related integral plasma membrane proteins with
seven transmembrane domains having their extracellular C
terminus and intracellular N terminus regions [depicted in
Figure 1]. AdipoR1 is abundantly synthesised and expressed
NH2 NH2
COOHCOOH
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Figure 1: Structure of adiponectin receptors—AdipoR1 and Adi-
poR2 (66.7% amino acid homology).
in skeletal muscle, whereas AdipoR2 is found predominantly
in liver [22]. Both receptors have also been described in pan-
creatic 𝛽-cells, macrophages, endothelial cells, and smooth
muscle cells within atherosclerotic plaques [23, 24]. C-
terminus of AdipoR1 possesses high affinity for gAD, whereas
adipoR2 exhibits intermediate affinity for both the gAD and
fAD. Overexpression and gene knockout experiments in
rodents have demonstrated the ability of these receptors to
activate AMP-activated protein kinase (AMPK), p38mitogen
activated protein kinase (p38 MAPK), and peroxisome-
proliferator-activated receptor-𝛼 (PPAR-𝛼) and to stimulate
fatty acid oxidation and glucose uptake in murine hepato-
cytes and C2C12myocytes [22]. Globular, trimeric, and high-
molecular-weight (HMW) adiponectin forms activate differ-
ent signal transduction pathways [25]. Additionally, osmotin,
a plant protein with structural similarities to mammalian
globular adiponectin, binds to adiponectin receptors and
activates AMPK in C2C12 myocytes [26].
Exercise training increases AdipoR1/R2 mRNA expres-
sion in human skeletal muscle [27], whereas no significant
change has been reported in human subcutaneous adipose
tissue during calorie restriction [28]. The expression levels of
AdipoR1 and AdipoR2 in skeletal muscle, as well as plasma
adiponectin concentrations, have been described to be lower
in individuals with a family history of type 2 diabetes mellitus
(T2DM) than in those with no family history [29]. The exp-
ression level of both receptors correlated positively with ins-
ulin sensitivity [29]. A study byZhang et al., 2010, haddemon-
strated significant reduction in expression of AdipoR2 in
both coronary arterioles and aortas of diabetic mice, with no
changes in AdipoR1 expression levels [30].
Another adiponectin-binding protein with a preference
forHMWadiponectinmultimers and no affinity for the trim-
eric adiponectin has been identified as T-cadherin [45]. Since
this protein is a glycosylphosphatidylinositol-anchored extra-
cellular protein devoid of any intracellular domain, themech-
anism explaining its role in adiponectin intracellular signall-
ing has not been fully clarified.
4. Leptin
Leptin, a 16 kDa protein, is an adipose-tissue specific adipo-
kine involved in regulation of food intake and energy haemo-
stasis [46]. Leptin also has multiple roles in carbohydrate and
lipid metabolism, reproductive system, and inflammatory
and immune reactions [47]. Leptin has been shown to exert
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Figure 2: Structure of leptin receptor isoforms—6 different iso-
forms of the leptin receptor Ob-R (a–f). Extracellular ligand-bind
domains of receptor isoforms are identical but they differ at the C-
terminus.
atherogenic, thrombotic, and angiogenic actions on the vas-
culature [48–50]. It has been linked extensively with obesity
leading to CVDs including atherosclerosis, myocardial infar-
ction, and stroke [51, 52].
Leptin acts on target cells through plasma membrane
receptors (Figure 2) and exists in at least six isoforms, Ob-
Ra through Ob-Rf, signalling predominantly via JAK/STAT
(Janus kinases/signal transducers, and activators of tran-
scription) pathway [53]. Functional leptin receptors (both
short and long forms of OB-R) have been identified on
endothelial cells [38, 54], and numerous studies link the pos-
sible mechanisms responsible for leptin-induced endothelial
dysfunction. JAK-2/IRS-2/PI3-K/Akt pathways and nuclear
translocation of STAT (signal transducer and activator of
transcription) proteins have been implicated to play a piv-
otal role in leptin-mediated effects in endothelial cells [53,
55]. Interestingly, in states of obesity despite a paradoxical
impairment of the satiety response, leptin resistance does not
extend to leptin mediated endothelial dysfunction [56–59].
Recent studies have demonstrated increased expression and
modulation of astrocytic leptin receptor subtypes (Ob-R) in
adult-onset obesity facilitating increased leptin transport via
the human brain endothelial cell barrier [60]. Although this
selective response of leptin has gained much attention, the
molecular basis remains poorly understood.
4.1. Adiponectin, Nitric Oxide (NO), and Endothelial Adhesion
Molecules. Decreased production of NO by the endothelial
cells is considered as the hallmark of endothelial dysfunction.
Adiponectin has been reported to increase NO production in
endothelial cells by the activation of phosphotidylinositol-3
(PI-3) kinase/Akt signalling pathway [61]. Furthermore, the
involvement of AMPK and protein kinase A [PKA, or cyclic
AMP- (cAMP-) dependent protein kinase] signalling have
also been implicated to play a major role in both adiponectin
induced NO production and suppression of endothelial
ROS generation, inhibiting endothelial NF-𝜅𝛽 (nuclear factor
kappa beta) signalling [32, 62–65].
Animal studies conducted in adiponectin knockout (KO)
mice have shown a significant reduction in endothelium-
dependent vasodilatation [66]. Adiponectin and lectin-like
oxidized LDL (ox-LDL) receptor- (LOX-) 1 have beendemon-
strated to exhibit a reciprocal pattern in states of endothelial
dysfunction and inflammatory insults. Adiponectin admin-
istration in apolipoprotein E (ApoE) knockout (KO) mice
restored NO-mediated endothelium-dependent vasorelax-
ation and decreased aortic LOX-1 expression, implicating
a key biological function of adiponectin in reducing sys-
temic oxidative mediators and ox-LDL uptake [67]. More
importantly, studies in T2DMmice have elucidated a similar
reciprocal regulation between adiponectin and TNF-𝛼 affect-
ing the regulation of both coronary and aortic endothelial
function. These effects seem to be regulated by a common
downstream transcription factor-NF-𝜅𝛽 [68]. Additionally,
in vivo studies have indicated the critical role of adiponectin
in alleviating sepsis-inducedmicrovascular dysfunction lead-
ing to blood brain barrier (BBB) dysfunction in the mouse
brain viamodulation of E-selectin expression [69].
Clinical studies have demonstrated impaired produc-
tion of eNOS in the vasculature consequently leading to
decreased endothelium-dependent vasorelaxation in subjects
with decreased adiponectin levels. Furthermore, adiponectin
drastically improves oxidized LDL induced decrease in eNOS
activity [36, 70]. More importantly, to simulate pathological
states of obesity and diabetes, the role of adiponectin in
hyperglycaemic/hyperinsulinaemic environments has been
studied. Xiao et al. have demonstrated a protective action
of gAd in alleviating endothelial dysfunction caused due to
intermittent hyperglycaemia, implicating the involvement of
Akt, AMPK, and eNOS signalling pathways [71]. The delete-
rious effects of hyperglycaemia in obese and diabetic subjects
extend to a concomitant decrease in circulating endothelial
progenitor cells (EPCs) leading to impaired endothelial rep-
air. Studies have indicated that gAd promoted EPCmigration
and tube formation and dose-dependently upregulated phos-
phorylation of eNOS, Akt, and augmented NO production.
Additionally, in vivo results have revealed that gAd rescued
high glucose induced impairment of EPC functions by restor-
ation of eNOS activity and vasculogenesis [37].
It is interesting to note that adiponectin induced activa-
tion of eNOS as well as increased production of NO by the
endothelial cells is crucial in mediating its anti-inflammatory
effects. In this context, in vivo studies have demonstrated that
pharmacological blockade of eNOS leads to decreased pro-
tective effect imparted by adiponectin, leading to increased
leukocyte adhesion by TNF-𝛼 [72].
Endothelial dysfunction includes the activation of
endothelial adhesionmolecular cascade critical in facilitating
the entry ofmacrophages into the vessel wall [73]. Circulating
low adiponectin levels in metabolic diseases like obesity and
diabetes have been linked to the triggering of an inflamma-
tory signalling cascade, leading to the early development of
atherosclerosis [74].The development of a similar scenario in
Adipoq–/– (adiponectin knock-out mice) mice further stren-
gthens the association between adiponectin and CVD [72].
Adiponectin replacement therapy reversed themicrovascular
inflammatory changes in these Adipoq–/– mice. Further-
more, adiponectin has been shown to inhibit the vascular infl-
ammatory response of endothelium to TNF-𝛼 induced activ-
ation of NF-𝜅𝛽 and increased expression of adhesion mole-
cules vascular cell adhesion molecule (VCAM-1), interc-
ellular adhesionmolecule (ICAM-1), and endothelial selectin
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(E-selectin) [32]. Functional effects induced by mediators of
systemic inflammation like TNF-𝛼 and subsequent intera-
ctions with adipokines have a significant influence in either
promoting or downregulating vascular insult.
4.2. Adiponectin and Endothelial Angiogenesis. Adiponectin
has been shown to induce in vitro angiogenesis in endothe-
lial cells via AMPK-eNOS pathway [31]. More importantly,
adiponectin replacement rectified ischemic stress induced
impaired angiogenesis in Adipoq–/– mice [75]. Studies con-
ducted in adiponectin-overexpressed mice brain (following
transfection with adenoassociated viral vector (AAV) con-
taining adiponectin gene) have shown a significant benefit
induced by adiponectin following ischemic insult. This pro-
tective action was related to adiponectin induced focal angio-
genesis involving VEGF and AMPK pathways [76]. On the
other hand, other groups have demonstrated the potent
inhibition of endothelial angiogenic events like migration
and proliferation by adiponectin [33], involving MAPK and
cAMP-PKA pathways [34]. Similar antiangiogenic effects of
adiponectin have been studied in tumour growth suppression
involving Rho kinase/IFN-inducible protein 10 and matrix
metalloproteinase 9 (MMP-9) [77].
4.3. Differential Effects of fAD and gAD. Numerous studies
have implicated the vasoprotective actions of fAD by reduc-
ing the expression of endothelial adhesion molecules and
inhibiting TNF-𝛼 induced cytokine production from macr-
ophages via NF-𝜅𝛽/cAMP-dependent pathway [32, 78–80].
Animal studies in Ad−/− (mice completely lacking adiponec-
tin) and Ad+/− (adiponectin-hemizygous mice) mice showed
an increased expression of E-selectins and VCAMs. More-
over, administration of gAd attenuated VCAM expression in
Ad−/− mice [72]. Adiponectin has been demonstrated to sup-
press VEGF-stimulated HCAEC migration via cAMP/PKA-
dependent signalling [34]. Clinical studies in patients with
acute coronary syndromes have shown a negative correlation
between circulating adiponectin levels and MMP-9/TIMP-1
ratio, an independent predictor of atherosclerotic plaque sta-
bility [80]. However, three independent studies have demon-
strated that gAd activates NF-𝜅𝛽 leading to activation of
the proinflammatory adhesion cascade, proliferation, and
increased procoagulability in endothelial cells and cardiac
fibroblasts [39, 40, 81].
Furthermore, studies by Hattori et al. have indicated the
suppression of cytokine induced inflammatory cascade via
NF-𝜅𝛽 by gAD, albeit with a prolonged response time. The
authors attribute this to desensitisation of the receptor, seen
in instances of cytokine overload. More recently, colocaliza-
tion studies conducted by Xu et al. have demonstrated that
adiponectin induces interaction between lymphotoxin- (LT-)
b receptor (LTBR) and human AdipoR1, subsequently result-
ing in inhibition of the NF-𝜅𝛽 pathway [82].
Studies have demonstrated the ability of leukocyte elasta-
se secreted by activated monocytes and neutrophils to cleave
the globular domain of adiponectin [21].This local generation
of gAd at sites of inflammation, namely, in atherosclerotic
lesions, could be having pathophysiological relevance given
the differential actions of multimeric forms of adiponectin.
In a study comparing the differential effects of fAd and gAd
in human aortic endothelial cells (HAEC), both peptides
upregulated NO production by AMPK-dependent pathways.
However, in contrast to fAd, gAd activated NF-𝜅𝛽 and p38
MAPK signalling pathways, resulting in cyclooxygenase-2
(COX-2) production and subsequently prostacyclin 2 [PGI]
release. This study further demonstrated that monocyte-
endothelial adhesion enhanced by gAD remained unaffected
with either abrogation of AdipoR1 [siRNA] signalling or
COX-2 [siRNA] downregulation, thereby suggesting indepe-
ndent mechanisms governing actions of fAd and gAd [41].
The obvious discrepancies between the experimental out-
comes could be due to the differences in the forms of adipo-
nectin used (Table 1). Additionally, endogenous production
of adiponectin by the endothelial cells needs to be considered
[83].
Recently, we undertook a study to investigate the effect
of gAD and fAD (Figure 3) on endothelial cell proliferation
as well as in vitro migration and angiogenesis in relation to
the induction of endothelial angiogenic factors, specifically,
MMP-2, MMP-9, and VEGF; furthermore, we examined the
involvement of the adiponectin receptors, that is, adiponectin
receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2),
within this context [35]. More importantly, given the connec-
tion between the coexistence of hyperglycaemia and systemic
inflammation with vascular disease in pathological states
such as diabetes mellitus, we also studied the interaction bet-
ween glucose and C-reactive protein (CRP) [a potent proi-
nflammatory protein], respectively, with gAD and fAD.
Finally, since AMP-activated protein kinase (AMPK), a
stress-activated protein kinase, and Akt have been implicated
as critical mediators of adiponectin induced angiogenesis
in both normoxic and ischemic tissues, we examined the
role of these signalling pathways in gAd induced endothelial
angiogenesis [31]. We found that gAd led to a significant
increase in in vitro endothelial proliferation, migration, and
angiogenesis with concomitant increase in MMP-2, MMP-9,
and VEGF gene and protein production, as well as MMP-2
andMMP-9 activation.The effect of gAd onVEGF appears to
be mediated by AdipoR1 whereas the effect of gAd on MMP-
2 and MMP-9 appears to be mediated by AdipoR1 and Adi-
poR2. On the other hand, only endothelial cell proliferation
was significantly increased by fAd and appears to bemediated
by AdipoR2; no significant effects on MMP-2, MMP-9, and
VEGF were observed. Ouchi et al. 2004 had reported that
mouse fAD stimulates in vitro migration and angiogenesis
and suggested that this effect may be beneficial in line with
the report by Shibata et al., 2004, who demonstrated that
adiponectin promotes ischemia-mediated revascularization
in adiponectin-knockout mice. It is important to note that
although in vitro angiogenic assays have been merited as
useful reporters in deciphering specific steps, they however
lack the complex interplay of multiple factors vital for in vivo
processes [31, 33]. Taken together, it remains unclear as to
whether our observations reflect on balance a beneficial or
detrimental effect of adiponectin.
Thus it seems imperative to study the local effects of
various multimers of adiponectin in situ, for instance, in
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Table 1: Differential effects of fAD, gAD, and leptin in endothelial cells.
Induced effect in
endothelial cells [EC]
fAD (dose and time duration of
response)
gAD (dose and time duration of
response)
Leptin (dose and time duration
of response)
Receptors AdipoR1 and AdipoR2 Predominantly AdipoR1 OB-R (both short and longforms)
In vitro proliferation,
migration, and
angiogenesis
HUVECs-30 ug/mL-24 hrs-
angiogenesis [31]
HAECs-30𝜇g/mL-24 hrs-
↓migration [32]
PAEs-1 𝜇g/mL-24 hrs-
↓proliferation and migration [33]
HAECs-0.5𝜇g/mL-24 hrs-↓VEGF
migration [34]
HMECs-3.0𝜇g/mL-24 hrs-
↓proliferation
[35]
BAECs-5mg/mL-↓ox-LDL
induced EC proliferation [36]
EPCs-20𝜇g/mL-24 hrs-
migration-angiogenesis [37]
HAECs-0.5𝜇g/mL 24 hrs-
↓VEGF induced EC migration
[34]
HMECs-3.0𝜇g/mL-24 hrs-
proliferation, migration, and
angiogenesis [35]
[(HUVECs)-(10–40 ng/mL)-
24 hrs]-proliferation and
angiogenesis [38]
EC inflammation and
mediators
[(HAECs)-50 ug/mL-18
hrs-↓TNF-𝛼 induced NF-𝜅𝛽 [32]]
[HUVECs-10 ug/mL-8 hrs]-
NF-𝜅𝛽 activation [39]
[(HUVECs)-3 ug/mL-5 hrs]-
↑procoagulability [40]
[(HAECs)-10 ug/mL-8 hrs]-
↑adhesion, VCAM-1/COX-2 via
NF-𝜅𝛽 pathways [41]
[(HUVECs)-10-ng/mL-1 hr]
NF-𝜅𝛽 activation, MCP-1
production, and ↑ROS
production [42]
[(HCAECs)-10 ng/mL-↑TF
expression and activity,
↑VCAM-1, ICAM-1, and
E-selectin expression and
EC-monocyte adhesion [43]]
eNOS and NO production
[(HUVECs)-30 ug/mL-]-AMPK-
eNOS phosphorylation
[31]
[(EPCs)-5𝜇g/mL-eNOS
phosphorylation and NO
production [37]]
[(HAECs)-10 ng/mL-eNOS
phosphorylation and ↑NO
production [44]].
The in vitro effects of fAD, gAD, and leptin differ on the concentration, time duration of peptide exposure, and the type of endothelial cells. BAECs: bovine
aortic endothelial cells, EC: endothelial cell, eNOS: endothelial nitric oxide synthase, EPCs: endothelial progenitor cells, E-selectin: endothelial selectin, fAD:
full length adiponectin, gAD: globular adiponectin, HAECs: human aortic endothelial cells, HCAECs: human coronary artery endothelial cells, HMECs:
human microvascular endothelial cells, HUVECs: human umbilical vein endothelial cells, ICAM-1: intercellular cell adhesion molecule, MCP-1: monocyte
chemoattractant protein-1, PAEs: porcine aortic endothelial cells, ROS: reactive oxygen species, TF: tissue factor, TNF𝛼: tumour necrosis factor alpha, VCAM-
1: vascular cell adhesion molecule, NF-𝜅𝛽: nuclear factor kappa beta, and VEGF: vascular endothelial growth factor.
atherosclerotic plaques, to ascertain the potential pro/anti-
inflammatory actions of this adipokine.
4.4. Leptin and Endothelial Cell Dysfunction. Leptin hasmul-
tiple proinflammatory and immune mediated effects on the
vasculature. On engagement with leptin receptors expressed
on vascular cell walls, leptin induces oxidative stress respon-
ses, increases MCP-1, TNF-𝛼, IL-6, and endothelin-1, and
potentiates proliferation, along with the expression of other
endothelial cell adhesion molecules, MMPs, VEGF, and imp-
aired smooth-muscle cell function, resulting in impaired
endothelium-dependent vasodilatation promoting hyperten-
sion and atherosclerosis [84]. Clinical studies have reported a
positive correlation between circulating leptin, plasma thro-
mbomodulin, and VCAM-1 levels [85].
4.5. Leptin Induced Endothelium Dependent and Indepen-
dent Vasodilation. Endothelium dependent leptin induced
vasorelaxation observed in rat arterial rings was promptly
inhibited by increasing extracellular calcium [86] and inhibi-
tion of NO synthase.Moreover, leptin has been demonstrated
to phosphorylate eNOS leading to NO release [44]. Intra-
arterial administration of leptin showed a similar vasoactive
response independent of NO in humans [87]. Additionally,
a direct vasorelaxive effect of leptin on smooth muscle cells
independent of endothelium was also observed in both rat
and human arterial samples [88, 89]. Acute hyperleptinemia
induced vasodilatory effects and this seemingly contradicts
the coexisting hypertension and increased leptin levels on
obesity. A plausible explanation for this could be attributed
to the acute and chronic effects of leptin on the vasculature.
Recent in vivo studies have revealed additional induction of
endothelial nNOS (neuronal nitric oxide synthase) expres-
sion by leptin as a compensatory mechanism to induce
endothelium-dependent relaxation in eNOS (−/−) mice [90].
More importantly, hyperleptinemia induced endothelial dys-
function may play a crucial role in the differential actions of
leptin.
4.6. Leptin Induced Endothelial Dysfunction and NO Pro-
duction. Experiments by Naseem have indicated that leptin
initiated upregulation of inducible NO synthase (iNOS),
which may or may not lead to net increased NO production
and paradoxically impairs endothelial function by inducing
oxidative stress [91]. Furthermore, a significant vasodilatory
response induced by leptin in lean Zucker rats failed to do so
in obese hyperleptinemic Zucker rats [92].
6 Journal of Diabetes Research
El
as
ta
se
Neutrophil
gAD fAD
Adipose tissue
Leptin
Adiponectin
gAD + inﬂammatory stimuli (glucose, CRP)
AdipoR1 AdipoR2
AMPK
AMPK, MAPK
cAMP-PKA
JAK2/IRS2/
PI3-K/Akt
STAT3
Proangiogenic
MMP-2/MMP-9
FGF-2/VEGF/TIMPs
Endothelial dysfunction
iNOS, NO, ROS
Proatherogenic
MCP-1, TNF-𝛼, IL-6,
VCAM-1, endothelin-1
Inﬂammation
NF-𝜅𝛽, TNF-𝛼, IL-2, IL-6,
MCP-1, ROS, Th1, TGF-𝛽
AMPK
Figure 3: Differential effects of leptin and adiponectin in vascular endothelium. Dual effects of gAD and fAD on endothelium with and
without inflammatory stimuli. Circulating fAD gets cleaved by leucocyte elastase (secreted from neutrophils) releasing globular domain
(gAD) fraction. AdipoR1 and AdipoR2 receptors following engagement with fAD, signals downstream activating the following pathways
(a) AMPK, (b) cAMP-PKA, (c) MAPK, and (d) PI3K-Akt. Activation of cAMP-PKA/AMPK causes increased NO production, decreased
ROS generation, suppression of NF-𝜅𝛽 pathway leading to reduction in IL-18, and endothelial adhesion molecule expression. These events
collectively lead to a decrease in EC permeability, motility, and migration. Activation of AMPK/PI-3k/Akt signalling pathway specifically
leads to eNOS phosphorylation and NO release. In vitro studies have shown that gAD independently activates NF-𝜅𝛽 via AdipoR1/AMPK-
Akt pathway. Proangiogenic/inflammatory effects of gAD have been shown to involve AMPK-Akt pathways. However, these pathways
(AMPK-Akt) also contribute to an opposite effect of gAD in coexisting states of hyperglycaemia and inflammation. In hyperglycaemic and
hyperinsulinaemic states, gAD improves endothelial dysfunction via activation of Akt-AMP-eNOS pathways and suppression of endothelial
ROS generation via inhibition of NF-𝜅𝛽 signalling. The binding of leptin to its receptor (OB-Rb) leads to the phosphorylation of Ob-
R/JAK2 complex. Subsequent activation of downstream signalling cascades including PI3k/Akt-STAT3 activation results in transcription of
genes [MCP-1, TNF-𝛼, IL-6/-2, and endothelin-1] involved in proatherogenic/angiogenic and inflammatory effects, potentiating endothelial
proliferation. Additionally, leptin signalling in ECs also activates endothelial cell adhesionmolecules,MMPs, andVEGF resulting in impaired
endothelium-dependent vasodilatation promoting hypertension and atherosclerosis.
As mentioned, leptin has been shown to induce oxidative
stress by increasing the formation of reactive oxygen species
(ROS), a key mediator of endothelial dysfunction [42, 93].
This generated ROS has potent peroxidant effects and thereby
reduces the bioavailability of NO in aortic endothelial cells
[93], vascular smooth muscle cells [84], and macrophages
[94]. Additionally, ROS further contributes to endothelial
dysfunction by upregulating proinflammatory cascades incl-
uding adhesion and chemotactic pathways in endothelial cells
[95].
It is interesting to note that genetically modified (ob/ob-
leptin knock out) mice maintain a relative hypotensive status
in comparison with their wild types. Leptin administration
in these mice promptly induces hypertension. This could be
attributed to the disturbance in the fine balance between the
sympathetic nervous system and endothelial cell mediated
regulation of vasomotor tone [96]. With respect to the regu-
lation of leptin receptors and endothelial dysfunction, a study
by Park et al. 2012 has revealed that leptin receptors in coro-
nary arterioles are downregulated in high-fat fed sedentary
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mice leading to endothelial dysfunction. However, when sub-
jected to exercise, the expression of leptin receptors in coro-
nary arterioles was restored along withmaintenance of eNOS
phosphorylation, leptin sensitivity, and redox balance [97].
4.7. Leptin and Endothelial Angiogenesis. As mentioned pre-
viously, leptin-mediated actions in endothelial cells, includ-
ing angiogenesis, primarily occur via the activation of Ob-
R. It is interesting to note the increased expressions of both
Ob-R and MMPs in atherosclerotic plaques, particularly the
endothelial lining of neointimal regions, suggesting the role
of leptin in mediating aberrant angiogenesis [98]. Both in
vivo and in vitro studies have demonstrated the activation
of endothelial Ob-R by leptin, leading to capillary tube for-
mation, a prerequisite for angiogenesis [38]. Bouloumie´ et al.
showed that leptin induced activation of mitogen-activated
protein kinase family ERK1/2 leads to an increase in endothe-
lial cell viability in serum-free media. Leptin has been shown
to upregulate key proangiogenic molecules like the gelati-
nases (MMPs, MMP-2/-9) and TIMPs. Additionally, leptin
has been shown to upregulate and act synergistically with the
key angiogenic mediators like FGF-2, VEGF, and its receptor
VEGFR1, stimulating vascular permeability, consequently
resulting in functional angiogenesis [99].
It is important to note that wound healing disorder (due
to deficient angiogenesis) in ob/ob mice is corrected by
both topical and systemic leptin administration but not in
fa/fa Zucker rats (rats with a recessive trait of the leptin
receptor), due to the absence of functional leptin receptors
[100]. In a recent study involving an obese NZO (mice with
phosphatidylcholine transfer protein mutation leading to
abnormal lipid homeostasis)micemodel, the angiogenic pot-
ential of leptin was found to be insignificant, perhaps due
to the relative inactivity of its receptor in these mice [101].
Studies in HUVECs have implicated the involvement of a
functional endothelial p38 (MAPK)/Akt/COX-2 signalling
axis for leptin’s proangiogenic effects and more importantly
this signalling pathway is regulated upstream by ObRb-
dependent activation of VEGFR2 receptor [102]. In vivo
findings have implicated increased mobilisation of vascular
progenitor cells mobilized from the bonemarrow in response
to leptin stimulation leading to angiogenesis. These effects of
leptin seem to be mediated via Ob-R induced activation of
NOX2 and MMP9 [103]. Additional studies have evidenced
the importance of an ObR-Src kinase-alpha v beta 5 cross
talk in leptin mediated functional effects in enhancing the
angiogenic potential of circulating angiogenic cells (CACs).
More importantly, CACs derived from obese, hyperleptine-
mic individuals were associated with relative insensitivity to
the angiogenic effects of leptin [104]. Leptin induced EPCs
and NO production has been shown to play critical roles
in melanoma tumour growth induction [105]. Extending
these findings to tumour angiogenesis, recent studies have
implicated intratumoral leptin to exert proangiogenic effects
stimulating tube formation and proliferation of endothelial
cells. More importantly, the authors have also demonstra-
ted the therapeutic potential of a peptide ObR antago-
nist in inhibiting these proangiogenic effects of leptin via
the VEGF pathway [106]. Interestingly, leptin induced pro-
liferation/migration as well as expression of proangiogenic
molecules in breast cancer has been recently demonstrated to
involve extensive crosstalk between Notch and interleukin-1
(NILCO) pathways [107].
4.8. Leptin and Vascular Inflammation. Leptin has been
shown to upregulate variousmediators of vascular inflamma-
tion like TNF-𝛼, IL-2, IL-6, MCP-1, ROS,Th1-type cytokines,
and TGF-𝛽 from endothelial cells and PBMCs [56, 108–110].
In vitro studies have demonstrated leptin induced increases in
tissue factor (TF) and cellular adhesion molecules (CAMs)
expression in human coronary endothelial cells (HCAECs)
via NF-𝜅𝛽 leading to increased procoagulant activity and
leukocyte adhesion [111]. Additional molecules pivotal in
vascular inflammation including PAI-1 (plasminogen acti-
vator inhibitor-1) and P-selectin have been documented to
be induced upon leptin treatment [112, 113]. Clinical studies
have shown a positive correlation with PAI-1, vWf, tPA, and
plasma fibrinogen levels and an inverse relationship with
protein C and tissue factor pathway inhibitor. These findings
clearly demonstrate a strong link with circulating leptin
and increased platelet activity observed in the metabolic
syndrome [114–117]. It is therefore not surprising to note
the decreased incidence of atherosclerosis in hyperlipidaemic
mice (ob/ob; apoE−/−) [118].
4.9. Leptin-Adiponectin Ratio and Interactions. As discussed
previously, converse actions of leptin and adiponectin in the
vascular system have been widely studied. In obesity and dia-
beticmetabolic abnormalities, coexistence of hypoadiponect-
inemia and hyperleptinemia is observed. Thereby, the leptin
to adiponectin ratio (L : A) is higher in these subjects. Various
clinical studies have been conducted to elucidate the rela-
tionship between L : A ratio and markers of atherosclerotic
disease including carotid intimamedia thickness (CIMT) and
pulse wave velocity [119–121]. In yet another clinical study,
L : A ratio has been demonstrated as a useful biomarker for
the prevalence of metabolic syndrome, in comparison with
either leptin or adiponectin levels on their own. Additionally,
visceral fatmass and cardiorespiratory fitness levels have been
documented to influence this ratio [122]. Subjects with eNOS
polymorphisms with or without hyperinsulinemia have a
higher L : A ratio and are more prone for cardiovascular
events, suggesting a genetic link in the associated risk factors
[123]. Labruna et al. have demonstrated that high serum L/A
ratio is positively correlated with serum triglyceride levels,
serving as surrogate markers of vascular inflammation in “at-
risk” young severely obese individuals, which is independent
of waist circumference (WC) and BMI [124]. Additionally,
L : A ratio represented a powerful independent predictor of
intima media thickness (IMT), correlating with anthropo-
metric, metabolic, and clinical parameters. Moreover the
correlation with this ratio was much stronger than when
compared individually [120]. Furthermore, components of
the metabolic syndrome were correlated positively with lep-
tin/HMW adiponectin ratio, independent of parameters
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including age, smoking status, exercise, low-density lipopro-
tein (LDL) cholesterol, and BMI [125].
However, in contrary to the above mentioned findings,
L : A ratio failed to establish any significant differences in dis-
ease parameters, in a study conducted in patients with severe
coronary heart disease [126]. It is noteworthy to mention
that these above mentioned studies do differ in patient char-
acteristics and pathological parameters leading to opposing
results.
5. Conclusions/Future Directions
Adipose tissue secreted factors or adipokines have been impl-
icated in facilitating communication between adipose tissue
and vasculature comprising the adipovascular axis. Both
proinflammatory and anti-inflammatory activities of these
secreted adipokines seem to be crucial in creating a hom-
eostatic responsewhich remains disturbed in states of adipose
tissue expansion. In addition to alterations in the circulating
levels, the local (i.e., tissue concentration) availability of the
activated forms of these adipokines has a significant bearing
in influencing vascular function. For example, it is important
to consider the actions of locally available gAD fragment
of adiponectin, which could potentially drive leptin-induced
effects. In-depth understanding of themechanisms and prop-
erties of adipokine-receptor interactions and downstream
signalling cascadesmay help in a clearer understanding of the
pathogenesis of obesity-linked disorders. Studies investigat-
ing the vascular effects of various multimeric/cleaved forms
of adipokines will help in developing novel therapeutic strate-
gies and targets in counteracting obesity-related metabolic
and CVDs. Additionally large multicentric clinical studies
with strict inclusion-exclusion metabolic criteria need to be
performed.
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